Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study

Conclusion IND/GLY treatment resulted in a significant reduction in mean daily RM use and an increase in days without RM use compared with SFC in patients with moderate-to-very severe COPD during 52 week treatment period.Reference 1. Jenkins CR et al. BMC Pulm Med. 2015; doi: 10.1186/s12890-015-0077-0.

Source: European Respiratory Journal - November 7, 2016 Category: Respiratory Medicine Authors: Fogel, R., Chapman, K. R., Vogelmeier, C. F., FowlerTaylor, A., Ayers, T., Thach, C., Whelan, S., Clerkin, K., Patalano, F., Banerji, D. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research